Literature DB >> 1990898

Plasma concentrations of midazolam in children following intranasal administration.

E J Walbergh1, R J Wills, J Eckhert.   

Abstract

Nasally administered midazolam appears to be a useful method for rapidly sedating children prior to the induction of anesthesia. We determined the peak plasma concentrations after intranasal administration of midazolam and compared this to plasma concentrations achieved after intravenously administered midazolam in 18 children between the ages of 14 months and 5 yr, who underwent elective closure of an asymptomatic atrial septal or ventricular septal defect. Preanesthetic medication was at the discretion of the attending anesthesiologist. Induction of anesthesia was with halothane in N2O and O2 via mask, and tracheal intubation was performed after the administration of fentanyl or sufentanil plus pancuronium. Anesthesia was maintained with these agents, and augmented with halothane or isoflurane. As soon as arterial access was established, the patient received 0.1 mg/kg of either intranasal or intravenous midazolam. Midazolam concentrations were measured by gas chromatography-mass spectrometry. Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min. Ten minutes after the administration of midazolam, the mean plasma concentration in the intranasal midazolam group was 57% of the concentrations in the group receiving midazolam intravenously. These results confirm the clinical impression that intranasal administration of midazolam rapidly achieves sedative plasma concentrations in children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990898     DOI: 10.1097/00000542-199102000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  23 in total

1.  Intranasal diamorphine for paediatric analgesia: assessment of safety and efficacy.

Authors:  J A Wilson; J M Kendall; P Cornelius
Journal:  J Accid Emerg Med       Date:  1997-03

2.  A comparison of the sedative effect of oral versus nasal midazolam combined with nitrous oxide in uncooperative children.

Authors:  I E Musani; N V Chandan
Journal:  Eur Arch Paediatr Dent       Date:  2015-05-05

3.  [Pharmacokinetics of intranasal Fentanyl.].

Authors:  H W Striebel; J Krämer; I Luhmann; I Rohierse-Hohler; A Rieger
Journal:  Schmerz       Date:  1993-06       Impact factor: 1.107

4.  Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures.

Authors:  J M Kendall; B C Reeves; V S Latter
Journal:  BMJ       Date:  2001-02-03

5.  Effects of GABAA kinetics on cortical population activity: computational studies and physiological confirmations.

Authors:  Sandrine Chemla; Frédéric Chavane
Journal:  J Neurophysiol       Date:  2016-02-24       Impact factor: 2.714

6.  Comparison of ease of administration of intranasal midazolam spray and oral midazolam syrup by parents as premedication to children undergoing elective surgery.

Authors:  Milthi Manoj; M V S Satya Prakash; Srinivasan Swaminathan; Rithu Krishna Kamaladevi
Journal:  J Anesth       Date:  2017-03-07       Impact factor: 2.078

7.  Oral midazolam premedication in children: the minimum time interval for separation from parents.

Authors:  M F Levine; I A Spahr-Schopfer; E Hartley; J Lerman; B MacPherson
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

8.  Sedation with nasal ketamine and midazolam for cryotherapy in retinopathy of prematurity.

Authors:  A Louon; J Lithander; V G Reddy; A Gupta
Journal:  Br J Ophthalmol       Date:  1993-08       Impact factor: 4.638

Review 9.  Alternative delivery systems for agents to treat acute agitation: progress to date.

Authors:  Kimberly Nordstrom; Michael H Allen
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 10.  Comparative review of the adverse effects of sedatives used in children undergoing outpatient procedures.

Authors:  J D'Agostino; T E Terndrup
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.